UNSPSC 41202002: Adenovirus serological reagents

In this classification, Adenovirus serological reagents are devices used in test to identify specific Adenovirus antibodies in serum. US FDA regulates Adenovirus serological reagents under 21 CFR 866.3020 and under FDA product code GOA.

UNSPSC 41202002 Adenovirus serological reagents is a Commodity code, but state and local procurement under this code shows minimal recent activity tied to adenovirus-specific testing. The recent opportunities the source identifies span HIV testing kits, syphilis reagents, sexually transmitted infection screening (gonorrhea and chlamydia NG/CT tests), drug testing supplies, and general laboratory services — none of which directly concern adenovirus serology. The Illinois Department of Public Health, City of Austin, Collin County (Texas), and Gwinnett County (Georgia) have posted solicitations in the code's window, but the work they are actually buying reflects communicable disease surveillance, criminal justice drug screening, and public health laboratory operations across a broader reagent and testing-kit landscape than adenovirus serology alone.

Activity concentrates in Texas and Illinois over the past four months. The Illinois Department of Public Health issued an emergency procurement (26482DPHOFCDIB52340) in May 2026 for Abbott HIV/Syphilis reagents and related supplies at $38,079.50 on a sole-source basis, and a follow-on change order notice (27482DPHOFCDIB53956) in September 2026 to increase statewide sexually transmitted infection testing volumes under an IFB, with responses due October 13, 2026. The City of Austin solicited rapid HIV test kits twice — through IFB 9100 AAM1023 (responses due July 17, 2026) and a rebid IFB 9100 AAM1023REBID (responses due September 3, 2026) — for approximately 375 test kits and 79 control kits annually. Collin County, Texas issued an RFP for offender specimen collection and drug testing services (RFP 2026-327, responses due July 23, 2026) covering 25,031 tests annually at an estimated value of $600,000. The code shows little recent activity directly aligned with adenovirus serological reagents as a distinct procurement category.